Ultime notizie per Steakholder Foods (NASDAQ:STKH) Azioni

Steakholder Foods

Steakholder Foods Ltd is engaged in transforming the alternative protein industries through its technology. The group specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These tools help manufacturers of all sizes efficiently produce foods that meet consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production. The company's expertise in creating alternative protein products replicating traditional meats' complex textures such as beef steaks, white fish, shrimp, and eel. It also explores the integration of cultivated cells, preparing for future advancements in food technology.

WIIM

Mister Car Wash shares are trading lower after UBS and Piper Sandler cut their respective price targets on the stock.

Morgan Stanley analyst Lee Simpson maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight and lowers the price target from $194 to $180.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on ARM Holdings, Lowers Price Target to $180

PBF Energy shares are trading lower after the company reported mixed Q2 financial results.

UPBD

Upbound Group shares are trading lower after the company issued Q3 sales guidance below estimates.

JMP Securities analyst Matthew Carletti maintains The Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Market Outperform and raises the price target from $185 to $200.

JMP Securities Maintains Market Outperform on The Hanover Insurance Gr, Raises Price Target to $200

AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of&nbsp;$14.98 billion</a>. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46752687/abbvie-reports-second-quarter-2025-financial-results" rel="noreferrer noopener">consensus of $3.23</a>.
Global net revenues from the immunology portfolio were&nbsp;$7.63 billion, up 9.5% (+9.2% on an operational basis), including-Skyrizi sales increased 62.2% (+61.8%) to $4.42 billion; Rinvoq sales reached $2.03 billion, an increase of 41.8% (+41.2%); and Humira sales fell 58.1% (-58.2%) to $1.18 billion.
Oncology portfolio generated sales of&nbsp;$1.68 billion, up 2.6% (+2.4%), including- Imbruvica&#8217;s net revenues were&nbsp;$754 million, down 9.5%; Venclexta&#8217;s revenues were&nbsp;$691 million, up 8.5% (+8.3%); and Elahere&#8217;s revenues were&nbsp;$159 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46001795/abbvies-migraine-drug-achieves-superiority-in-preventing-headaches-compared-to-generic-treatment-in-head-to-head-trial" rel="noreferrer noopener">AbbVie&#8217;s Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial</a>
Neuroscience portfolio sales were&nbsp;$2.68 billion, up 24.2% (+24%), including-Vraylar net revenues were&nbsp;$900 million, up 16.3%; and Botox Therapeutic&#8217;s net revenues were&nbsp;$928 million, up 14.1% (+14.2%).
<h2 class="wp-block-heading">Outlook</h2>
AbbVie&nbsp;raises its fiscal 2025 adjusted earnings <a target="_blank" href="https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term" rel="noreferrer noopener">from&nbsp;$11.67-$11.87&nbsp;per share</a> to&nbsp;$11.88-$12.08&nbsp;compared to the analysts&#8217; estimate of&nbsp;$12.24.
This includes an unfavorable impact of&nbsp;55 cents&nbsp;per share related to acquired IPR&amp;D and milestones expense incurred year-to-date through the second quarter of 2025.
<h2 class="wp-block-heading">Key Takeaways From The Earnings Call</h2>
During the earnings call, the company provided important insights into its financial outlook and strategic positioning amid evolving market conditions.
It emphasized that its exposure to tariffs is not expected to be significantly greater than that of its industry peers. Thanks to proactive inventory management measures, the firm believes it is largely insulated from tariff-related disruptions for the remainder of the year.
For the third quarter, the company projects net revenues of approximately $15.5 billion, buoyed by an anticipated 1% favorable impact from foreign exchange fluctuations on sales growth.
The discussion also highlighted a regulatory development under the One Big Beautiful Bill Act, which exempts drugs with multiple orphan designations from Inflation Reduction Act (IRA) negotiations.
This exemption stands as a notable advantage for the company&#8217;s cancer therapy drug, Venclexta, potentially preserving its competitive positioning and pricing dynamics in a challenging environment.
Turning to its flagship product Humira, the company acknowledged that access within the U.S. market is expected to decline progressively throughout the latter half of 2025, as an increasing number of health plans adopt exclusionary formularies that limit the drug&#8217;s availability.
On a more optimistic note, the company conveyed strong confidence in its Parkinson&#8217;s disease portfolio. It described these assets collectively as possessing the potential to become a multi-billion-dollar growth engine over the long term, signaling an important avenue for future revenue expansion and pipeline diversification.
<h2 class="wp-block-heading">Rinvoq Achieves Strong Results In Severe Alopecia Areata Trial</h2>
On Wednesday, AbbVie released topline results from the first of two pivotal studies of the Phase 3 UP-AA program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 83.8 (approximately <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">16% scalp hair coverage)</a>.
In Study 2, both doses of upadacitinib achieved the primary endpoint, with 44.6% and 54.3% of patients treated with upadacitinib 15 mg and 30 mg, respectively, reaching 80% or more scalp hair coverage (SALT score ≤ 20) at week 24, compared to 3.4% of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46719124/abbvie-announces-positive-topline-results-from-phase-3-up-aa-trial-evaluating-upadacitinib-rinvoq-" rel="noreferrer noopener">patients receiving placebo</a>.
36.0% and 47.1% of patients treated with upadacitinib 15 mg and 30 mg, respectively, reached 90% or more scalp hair coverage (SALT ≤ 10), compared to 1.4% of patients receiving placebo at week 24.
Additional key secondary endpoints that were met included the percentage of subjects with improvements in eyebrows and eyelashes, as well as the percentage of subjects with complete scalp hair coverage (SALT=0) with both doses of upadacitinib at week 24.
Price Action: ABBV stock is trading higher by 2.51% to $194.06 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46748321/waymo-cars-involved-in-collision-at-phoenix-airport-video-surfaces-online" target="_blank" rel="noreferrer noopener">Waymo Cars Involved In Collision At Phoenix Airport, Video Surfaces Online</a></li>
</ul>
Photo via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

Movers

General

ABBV

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

Morgan Stanley analyst Ravi Shanker maintains ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) with a Overweight and lowers the price target from $140 to $130.

ARCB

Morgan Stanley Maintains Overweight on ArcBest, Lowers Price Target to $130

Vontier shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance.

DFIN

Donnelley Financial Solutions shares are trading lower after the company reported worse-than-expected Q2 revenue results and issued Q3 sales guidance below estimates.

Morgan Stanley analyst Eric Serotta maintains Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) with a Equal-Weight and raises the price target from $57 to $62.

Morgan Stanley Maintains Equal-Weight on Altria Group, Raises Price Target to $62

Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) reported second-quarter adjusted earnings per share of 94 cents, missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46753122/kellanova-reports-2025-second-quarter-results" rel="noreferrer noopener">analyst consensus estimate of $1</a>.
Powered by brands including Pringles, Cheez-It, Pop-Tarts, Kellogg&#8217;s Rice Krispies, and more, Kellanova&#8217;s quarterly <a target="_blank" href="https://s203.q4cdn.com/897568180/files/doc_financials/2025/q2/K-2Q-2025-RESULTS.pdf" rel="noreferrer noopener">sales </a>of $3.203 billion (down 0.3% year over year) outpaced the Street view of $3.197 billion.
North America&#8217;s reported and organic net sales decreased by 4% during the second quarter, as volume declined amidst prolonged softness in snacking and frozen categories.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46756444/comcast-rides-high-on-theme-park-and-peacock-success" rel="noreferrer noopener">Comcast Rides High On Theme Park And Studio Success</a>
Europe&#8217;s reported net sales increased 2% year-over-year in the second quarter, as positive foreign currency translation and improved price/mix more than offset a decline in volume related to prolonged demand softness in the snacks and cereal categories, as well as disruptions to orders from specific large customers.
Reported operating profit in the second quarter decreased by 11% year-on-year due to a negative swing in mark-to-market impacts and the profit impact of lower net sales outside Africa.
On an adjusted basis, which excludes mark-to-market impacts and one-time charges, operating profit decreased by 5%.
Adjusted gross profit in the quarter under review totaled $1.114 billion, lower than $1.164 billion a year ago. Adjusted gross margin contracted to 34.8% from 36.5% a year ago. Adjusted operating margin contracted to 14.9% from 15.7%.
The company exited the quarter with cash and equivalents worth $354 million.
On August 14, 2024, Mars, Incorporated announced a definitive agreement to acquire Kellanova for $83.50 per share in cash. Shareholders approved the deal on November 1, 2024, and the transaction is expected to close by the end of 2025, pending regulatory approvals and customary conditions.
Due to the pending merger with Mars, Kellanova will not be providing forward-looking guidance.
Price Action: K shares are trading higher by 0.19% to $79.97 at last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46734079/whats-fueling-paypals-post-earnings-skepticism" target="_blank" rel="noreferrer noopener">What&#8217;s Fueling PayPal&#8217;s Post-Earnings Skepticism?</a></li>
</ul>
Photo: Shutterstock

Cheez-It Maker's Q2 Profit Crumbles: Sales Beat, But Merger Clouds Outlook

Rumors

IPOs

Shoulder Innovations IPO Indicating $15.50-$16.50/Share; IPO Priced At $15/Share On 5M Shares

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>BMO Capital analyst Brian Pitz upgraded eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) from Market Perform to Outperform and raised the price target from $70 to $102. eBay shares closed at $77.56 on Wednesday. <a href="https://www.benzinga.com/quote/ebay/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Jackson Ader upgraded Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from Sector Weight to Overweight and announced a $630 price target. Microsoft shares closed at $513.24 on Wednesday. <a href="https://www.benzinga.com/quote/msft/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Joseph Moore upgraded the rating for Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) from Underweight to Equal-Weight and raised the price target from $74 to $100. Teradyne shares closed at $107.65 on Wednesday. <a href="https://www.benzinga.com/quote/ter/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Christopher LeFemina upgraded Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) from Hold to Buy and raised the price target from $135 to $170. Nucor shares closed at $142.95 on Wednesday. <a href="https://www.benzinga.com/quote/nnue/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Christopher Allen upgraded Stifel Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) from Neutral to Buy and boosted the price target from $115 to $135. Stifel Financial shares closed at $114.08 on Wednesday. <a href="https://www.benzinga.com/quote/sf/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MSFT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31111505/image-508-1024x560.png" alt="" class="wp-image-1009385" style="width:620px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31111505/image-508-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31111505/image-508-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31111505/image-508-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/31111505/image-508.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46756402/top-2-risk-off-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Risk Off Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Photo via Shutterstock

Upgrades

Markets

Trading Ideas

EBAY

MSFT

This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Waystar Holding shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance above estimates.

CCRD

CoreCard shares are trading higher after Euronet announced it will acquire the company for $248 million through an all-stock merger.

When it comes to managing your retirement savings, personal finance expert <a href="https://www.benzinga.com/personal-finance/management/25/07/46648661/after-losing-her-husband-and-father-she-turned-to-spending-now-shes-asking-suze-orman-if-an-inherited-ira-can-pay-off-her-41k-debt">Suze Orman</a> has a clear message: be cautious about hiring investment professionals, especially if you&#8217;re already seeing strong returns with index funds.
Orman recently addressed this topic on her "<a href="https://omny.fm/shows/suze-ormans-women-and-money/ask-kt-suze-anything-how-can-i-get-a-mega-retirement-account">Women &amp; Money</a>" podcast after a listener named Chad asked whether he should turn over his retirement savings to an asset manager.
<h2 class="wp-block-heading">A Listener's Dilemma: Should I Hire an Investment Professional?</h2>
Chad, 59, said he's been consistently investing in S&amp;P 500 mutual funds and wondered if it might be time to hire a professional. He had already interviewed four advisors, with fees ranging from 1.1% to 1.5% of total assets. He liked a couple of them and wanted to know if their rates were reasonable — and if hiring one would be worth it.
Don't Miss:
<ul class="wp-block-list">
<li>Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
<h2 class="wp-block-heading">The S&amp;P 500's Performance Speaks Volumes</h2>
Orman praised Chad's investing strategy, pointing out how well the <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46527393/the-last-time-this-warning-flashed-sp-500-crashed-the-most-since-2008">S&amp;P 500</a> has performed over the past 15 years. She gave an example:
<ul class="wp-block-list">
<li>A $10,000 investment in the S&amp;P 500 starting in 2009 would have grown at an average annual rate of 17.1%.</li>
<li>Even starting in 2010, the average return would still be around 12.1%.</li>
</ul>
In both cases, the growth is considered excellent by long-term investment standards.
<h2 class="wp-block-heading">Fees Can Eat Into Your Returns</h2>
The concern, according to Orman, isn't whether an advisor is likeable — it's whether they can consistently deliver returns high enough to make up for the fees they charge.
"Very few asset managers truthfully can outperform the Standard and Poor's 500 index," she said.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a>
Orman encouraged investors to ask potential advisors for proof of their performance — ideally over a 10- to 15-year period. If their average return doesn't beat the S&amp;P 500 by at least 5%, the advisor's fee could end up costing you more than it&#8217;s worth.
To illustrate this, she broke down the numbers:
<ul class="wp-block-list">
<li>Over 15 years, a 1.5% annual fee could cost an investor about $14,000 more per $10,000 invested compared to sticking with the index.</li>
<li>Even a lower 1.1% fee could result in around $8,000 less in returns.</li>
</ul>
<h2 class="wp-block-heading">When a Financial Advisor Might Make Sense</h2>
Orman isn't completely against hiring professionals. In some cases, an advisor can be valuable — especially for those who need help with broader <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/01/42805298/with-the-new-generation-beta-come-new-financial-planning-challenges-and-opportunities">financial planning</a>, tax strategies, or managing large or complex portfolios.
However, for someone like Chad, who's been doing well with index funds and understands the importance of consistency and long-term investing, Orman suggested staying the course.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">The Bottom Line</h2>
If your current strategy is working — especially if you&#8217;re in a low-cost, diversified fund like the S&amp;P 500 — paying a hefty management fee may not add value.
Orman's advice is simple: don't hand over your retirement savings unless the advisor can prove they consistently beat the market after fees. Otherwise, she says, "It is a waste of your money."
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Personal Finance

'Very Few Asset Managers Can Outperform The S&P 500 Index' – Suze Orman's Warning Against Hiring Investment Professionals

JMP Securities analyst Steven Delaney maintains Redwood Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWT#NYSE">RWT</a>) with a Market Outperform and lowers the price target from $7.5 to $7.

JMP Securities Maintains Market Outperform on Redwood Trust, Lowers Price Target to $7

OTRK

On July 29, Ontrak Board Decides To Cease Operations; Terminates Employment Of Executive Officers; To Terminate All Employees On July 31, 2025

Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) has outperformed the market over the past 15 years by 2.47% on an annualized basis producing an average annual return of 14.73%. Currently, Chemed has a market capitalization of $6.15 billion. 
Buying $100 In CHE: If an investor had bought $100 of CHE stock 15 years ago, it would be worth $776.17 today based on a price of $420.41 for CHE at the time of writing.
<h3>Chemed's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753974924_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Chemed 15 Years Ago Would Be Worth Today

Wells Fargo analyst Zachary Fadem maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Overweight and raises the price target from $375 to $415.

WING

Wells Fargo Maintains Overweight on Wingstop, Raises Price Target to $415

Press Releases

Steakholder Foods Shares Letter from CEO Arik Kaufman

Steakholder Foods® Secures $250,000 in Third SIIRD Grant Installment

Steakholder Foods® Announces $1.25 Million Private Placement and $8 Million Equity Line of Credit Funding Mechanism

Steakholder Foods Reports 2024 Financial Results and Provides Business Update

Steakholder Foods Announces ADS Ratio Adjustment

Contracts

Steakholder Foods Announces Signing of Investment and Convertible Loan Agreements, and Memorandum of Understanding for Proposed Transformative Acquisition of Twine Solutions

Power Metallic Mines (TSXV: PNPN | OTCQB: PNPNF) Issues Summer 2025 "BIG Picture" Exploration Update – More Stocks Inside

First Steakholder-Formulated Plant-Based Fish Products Rolled Out in Retail Outlets

Steakholder Foods Ltd. Announces Pricing of $2.5 Million Public Oﬀering

Legal

Steakholder Foods Receives Positive International Search Report for Patent Covering HD144 Fish Printer's DLS®-Based Drop-on-Demand Printing System

AIRI

BTCM

CGTX

PNPNF

SAFX

SNYR

STKH

TSXV:PNPN

Branchout Food

Australian Oilseeds Holdings Limited - Ordinary Shares

Australian Oilseeds Hldgs

Australian Oilseeds Holdings Limited - Warrant

Farmmi

CIMG

Coffee Holding Co

Moolec Science

Oriental Rise Holdings Limited - Ordinary Shares

Oriental Rise Holdings

TDH Hldgs

Planet Green Holdings

Rocky Mountain Chocolate Factory, Inc. - Common Stock

Rocky Mountain Chocolate

Sow Good

Steakholder Foods Ltd. - American Depositary Shares

Top Wealth Group Holding Limited - Class A Ordinary Shares

Top Wealth Group

Screenshot 2024-02-28 at 8.56.12 PM

Emerging Markets

Steakholder Foods (NASDAQ: STKH) Redefines Plant-Based Products: Where Sustainability Meets Culinary Innovation

Screenshot 2023-12-15 at 11.26.50 PM

Movers & Shakers

Interview

On The Menu: A 3D Printed Steak – Meet This Innovator Of Meat Alternatives

Comments

Steakholder Foods

Notizie

Ultime notizie per Steakholder Foods (NASDAQ:STKH) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO